ClinicalTrials.gg
CompletedNCT01999972Updated Sep 24, 2020Results posted

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

A Phase 1 interventional study of axitinib and crizotinib in Advanced Solid Tumors, sponsored by Pfizer. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-24.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Carcinoma by Pfizer — 6 open to participants now, 6 under way, 2 of them phase 3. Carcinoma · Pfizer.

Enrollment
18th of 24
50 · median 98
Started
2014
the only one that year
Phase 1
9 of 27
2 open now
Registered
19th of 27
by date

Among the 27 studies in Carcinoma by Pfizer, this one is the 18th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2014, is one of 9 in phase 1, and was the 19th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

6 of the 27 studies in Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Carcinoma by Pfizer, or all of them as a file.
02

Study summary

Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majority of patients will eventually develop evasive resistance. It is proposed that mesenchymal-epithelial transition factor (c-MET) and its ligand hepatocyte growth factor (HGF or scatter factor) contribute to VEGF inhibitor resistance, such that combining a c-MET inhibitor with a VEGF inhibitor will provide additional clinical activity compared to VEGF inhibitor alone. This hypothesis will be tested using the cMET/ALK inhibitor, crizotinib, in combination with the VEGF inhibitor, axitinib.Since this will be the first study of axitinib given in combination with crizotinib, the study will primarily assess the safety and tolerability of the combination regimen.

03

Conditions studied

  • Advanced Solid Tumors

Browse trials for

Keywords

  • Carcinoma
  • Renal Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis - Dose Escalation Phase: or cytologically confirmed diagnosis of advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available.
  • Diagnosis - Dose Expansion Phase: Histologically or cytologically confirmed advanced RCC with a component of clear cell subtype
  • Dose Expansion Phase: at least one measureable lesion as defined by [Response Evaluation Criterion in Solid Tumors] version 1.1.
  • [Eastern Cooperative Oncology Group] Performance Status 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Major surgery \<4 weeks or radiation therapy \<2 weeks of patient registration.
  • History of or known active seizure disorder, , spinal cord compression, or carcinomatous meningitis, or new evidence of brain or .
  • Dose Expansion Phase only: diagnosis of any other within 2 years prior to registration.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Axitinib in combination with crizotinib, escalation phase

    Dose Escalation Advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available

    Drug: axitinib · Drug: crizotinib

  • Experimental
    Expansion Phase Cohort 1

    Dose Expansion, Cohort 1: axitinib in combination with crizotinib Advanced renal cell cancer \[RCC\] with no prior systemic therapy

    Drug: axitinib · Drug: crizotinib

  • Experimental
    Expansion Phase Cohort 2

    Dose Expansion, Cohort 2: axitinib in combination with crizotinib Advanced renal cell cancer with at least one but no more than two prior systemic treatment regimens directed at advanced RCC

    Drug: axitinib · Drug: crizotinib

Interventions

  • Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.

  • Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.

  • Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.

  • Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.

  • Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.

  • Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.

06

What researchers measure

Primary outcomes

  1. Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs)

    Toxicity as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. DLT defined as any following events attributable to any (axitinib or crizotinib) or both agents in combination: hematologic (Grade 4 neutropenia, absolute neutrophil count\<1000/mm\^3 with single temperature of \>38.3 degrees celsius or sustained temperature of 38 degrees celsius for \>1 hour; \>=Grade 3 neutropenic infection; \>=Grade 3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia), non-hematologic (\>=Grade 3 toxicities \[except asymptomatic hypophosphatemia, hyperuricemia without signs, symptoms of gout, and tumor lysis syndrome\], nausea, vomiting or diarrhea persisted at Grade 3 or 4 despite maximal medical therapy; Grade 3 hypertension if persistent despite anti-hypertensives); In asymptomatic participant, Grade 3 QTc prolongation (QTc\>=501 msec) if persisted after correcting reversible causes, and failure to deliver \>=75 percent (%) of dose of each study drug.

    Time frame: Cycle 1 (28 days)

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drugs (crizotinib and axitinib) without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

    Time frame: First dose of study drug until 28 days after last dose (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)

  2. Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drugs (crizotinib and axitinib) in a participant who received study drugs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

    Time frame: First dose of study drug until 28 days after last dose (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)

  3. Number of Participants With Grade 3 or Higher Adverse Events (AEs) as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03

    An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 = death. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

    Time frame: First dose of study drug until 28 days after last dose (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)

  4. Number of Participants With Clinically Significant Laboratory Abnormalities Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03: Hematological Test Abnormalities

    Laboratory parameters included hematological and biochemistry parameters. Hematological parameters included haemoglobin (anemia, haemoglobin increased), lymphocytes (lymphopenia, lymphocyte count increased), neutrophils, platelets and white blood cells. Number of participants with hematological abnormalities by grades (as per NCI CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

    Time frame: Baseline up to end of treatment (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)

  5. Number of Participants With Clinically Significant Laboratory Abnormalities Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03: Biochemistry Test Abnormalities

    Laboratory parameters included hematological and biochemistry parameters. Biochemistry parameters/abnormalities included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia and gamma glutamyl transferase Number of participants with biochemistry test abnormalities by grades (NCI CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

    Time frame: Baseline up to end of treatment (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)

  6. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment Visit

    Time frame: Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 6, 12, 24; and end of treatment (up to a maximum duration of 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)

  7. Change From Baseline in Pulse Rate at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment

    Time frame: Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 6, 12, 24; and end of treatment (any time up to a maximum duration of 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)

  8. Change From Baseline in Body Weight at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment

    Time frame: Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 6, 12, 24; and end of treatment (any time up to a maximum duration of 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)

  9. Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG-PS) to Worst Value

    ECOG-PS: used to assess how disease affected the daily living abilities of participant. It ranges on the scale from: 0-5 (0=fully active/able to carry on all pre-disease activities without restriction;1=restricted in physically strenuous activity but ambulatory/able to carry out light/sedentary work;2=ambulatory \[for more than (\>)50%of waking hours\], capable of all self-care but unable to carry out any work activities;3=capable of limited self-care, confined to bed or chair \[for \>50% of waking hours\];4=completely disabled, not capable of any self-care, totally confined to bed or chair;5= dead, higher score=more functional impairment) and changes to worst status scores were presented. Baseline value=value collected prior to first dose of study drug on Cycle 1 Day 1. Worst post-baseline value=worst value between first dose of any study drug and end of treatment (EOT) visit. Shift to low refers to lower than Baseline value; shift to high refers to higher than baseline value for ECOG-PS.

    Time frame: Baseline, End of Treatment (up to Cycle 35 [for Part 1] and up to Cycle 35 [for Part 2], each cycle 28 days)

  10. Number of Participants With Maximum Increase From Baseline in QTc Interval

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Number of participants with maximum increase from baseline of less than (\<) 30 milliseconds (msec), 30 to \<60 msec and greater than or equal to (\>=) 60 msec were reported.

    Time frame: Baseline, End of Treatment (up to Cycle 35 [for Part 1] and up to Cycle 35 [for Part 2], each cycle 28 days)

  11. Maximum Observed Plasma Concentration (Cmax) of Axitinib and Crizotinib

    Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.

    Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15

  12. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib and Crizotinib

    Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.

    Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15

  13. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Axitinib and Crizotinib

    Area under the plasma concentration versus time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours. Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.

    Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15

  14. Apparent Oral Clearance (CL/F) of Axitinib and Crizotinib

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent oral clearance was obtained by dividing study drug dose with AUCtau, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval. Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.

    Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15

  15. Apparent Volume of Distribution (Vz/F) of Axitinib and Crizotinib

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15

  16. Percentage of Participants With Objective Response

    Percentage of participants with objective response based on assessment of confirmed complete response \[CR\] or confirmed partial response \[PR\] according to Response Evaluation Criteria In Solid Tumors \[RECIST\] version1.1 were reported. Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

    Time frame: From Baseline until disease progression or death, whichever occurred first (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)

  17. Dose Expansion Part: Duration of Response

    Duration of response (as per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as the time (in months) from first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) until the first date that recurrent, progressive disease, or death (whichever occurred first). CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. Progression was defined as \>= 20 percent increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.

    Time frame: From first objective response until first recurrent, disease progression, or death, whichever occurred first (up to 35 cycles, each cycle 28 days)

  18. Dose Expansion Part: Progression-Free Survival (PFS)

    PFS (as per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as the time (in months) from start of study treatment to first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date minus date of first dose of study medication plus 1) divided by 30.44. Progression was defined as \>= 20 percent increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions. PFS was not estimated in Dose Expansion Cohort 2 due to small sample size.

    Time frame: From Baseline until disease progression or death, whichever occurred first (up to 35 cycles, each cycle 28 days)

  19. Dose Expansion Part Cohort 1: Levels of Serum Soluble Protein Biomarkers

    Serum soluble protein biomarkers included angiopoietin-2, Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor Receptor 3 (VEGFR 3). Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.

    Time frame: Baseline, Cycle 2 Day 1, end of treatment (up to 35 cycles, each cycle 28 days)

  20. Dose Expansion Part Cohort 1: Change From Baseline in Serum Concentration of Circulating microRNAs (miRNA) at End of Treatment

    Time frame: Baseline, end of treatment (up to 35 cycles, each cycle 28 days)

  21. Dose Expansion Part Cohort 1: Percentage of c-MET Positive Tumor Cell at Baseline in Relation to Objective Response Rate (ORR)

    Percentage of c-MET positive tumor cell for objective response (complete response \[CR\] + partial response \[PR\]) is reported. Objective response was defined as CR and PR. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.

    Time frame: Baseline

  22. Dose Expansion Part Cohort 1: Level of Plasma Soluble Protein Biomarker (c-MET)

    Plasma soluble protein biomarker included c-MET. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.

    Time frame: Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 3, 5; end of treatment (up to 35 cycles, each cycle 28 days)

  23. Dose Expansion Part Cohort 1: Ratio of Serum Soluble Protein Biomarkers Level to Baseline Biomarkers Level by Each Timepoint

    Serum soluble protein biomarkers included angiopoietin-2, Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor Receptor 3 (VEGFR3). Ratio=value of serum soluble protein biomarkers at each time point to the value at baseline. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.

    Time frame: Baseline, Cycle 2 Day 1, end of treatment (up to 35 cycles, each cycle 28 days)

07

Results

Posted Jun 21, 2019

Participant flow

This study was conducted in 2 parts: Part 1 (Dose escalation part to determine maximum tolerated dose \[MTD\] of axitinib in combination with crizotinib), Part 2 (Dose expansion part to assess the safety and tolerability of axitinib in combination with crizotinib at MTD determined in Part 1).

Dose Escalation Part
Participant flow — Dose Escalation Part
MilestoneDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Started5351100
Treated5341000
Completed000000
Not completed5351100
Withdrew: Participant refused further follow-up101100
Withdrew: Death010000
Withdrew: Enrolled but not treated001100
Withdrew: Disease progression323600
Withdrew: Adverse event000200
Withdrew: Global deterioration of health status100100
Dose Expansion Part
Participant flow — Dose Expansion Part
MilestoneDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Started0000217
Treated0000217
Completed000000
Not completed0000217
Withdrew: Death000021
Withdrew: Disease progression000093
Withdrew: Sponsor decision000010
Withdrew: Adverse event000042
Withdrew: Participant's non-compliance000001
Withdrew: Participant refused further follow-up000040
Withdrew: Changed to standard of care000010

Outcome measures

PrimaryDose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs)

Toxicity as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. DLT defined as any following events attributable to any (axitinib or crizotinib) or both agents in combination: hematologic (Grade 4 neutropenia, absolute neutrophil count\<1000/mm\^3 with single temperature of \>38.3 degrees celsius or sustained temperature of 38 degrees celsius for \>1 hour; \>=Grade 3 neutropenic infection; \>=Grade 3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia), non-hematologic (\>=Grade 3 toxicities \[except asymptomatic hypophosphatemia, hyperuricemia without signs, symptoms of gout, and tumor lysis syndrome\], nausea, vomiting or diarrhea persisted at Grade 3 or 4 despite maximal medical therapy; Grade 3 hypertension if persistent despite anti-hypertensives); In asymptomatic participant, Grade 3 QTc prolongation (QTc\>=501 msec) if persisted after correcting reversible causes, and failure to deliver \>=75 percent (%) of dose of each study drug.

Time frame:
Cycle 1 (28 days)
Reported as:
Count of participants · Participants
Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs)
ParticipantsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg
Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs)0000
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drugs (crizotinib and axitinib) without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

Time frame:
First dose of study drug until 28 days after last dose (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
AEs53310217
SAEs220583
SecondaryNumber of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Treatment-related AE was any untoward medical occurrence attributed to study drugs (crizotinib and axitinib) in a participant who received study drugs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

Time frame:
First dose of study drug until 28 days after last dose (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
AEs4339216
SAEs100212
SecondaryNumber of Participants With Grade 3 or Higher Adverse Events (AEs) as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03

An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 = death. Treatment-emergent were events between first dose of study drug and until 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

Time frame:
First dose of study drug until 28 days after last dose (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher Adverse Events (AEs) as Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03
ParticipantsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Grade 3 or 4 AEs3318196
Grade 5 AEs010020
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03: Hematological Test Abnormalities

Laboratory parameters included hematological and biochemistry parameters. Hematological parameters included haemoglobin (anemia, haemoglobin increased), lymphocytes (lymphopenia, lymphocyte count increased), neutrophils, platelets and white blood cells. Number of participants with hematological abnormalities by grades (as per NCI CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame:
Baseline up to end of treatment (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03: Hematological Test Abnormalities
ParticipantsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Anemia: Grade 11102103
Anemia: Grade 2000122
Anemia: Grade 3000010
Anemia: Grade 4000000
Hemoglobin increased: Grade 1010110
Hemoglobin increased: Grade 2000000
Hemoglobin increased: Grade 3000000
Hemoglobin increased: Grade 4000000
Lymphopenia: Grade 1100100
Lymphopenia: Grade 2001274
Lymphopenia: Grade 3100220
Lymphopenia: Grade 4000000
Neutrophils (absolute): Grade 1000010
Neutrophils (absolute): Grade 2000001
Neutrophils (absolute): Grade 3000000
Neutrophils (absolute): : Grade 4000000
Platelets: Grade 1011262
Platelets: Grade 2000000
Platelets: Grade 3000000
Platelets: Grade 4000000
White blood cells: Grade 1101061
White blood cells: Grade 2000011
White blood cells: Grade 3000000
White blood cells: Grade 4000000
Lymphocyte count increased: Grade 1000000
Lymphocyte count increased: Grade 2000000
Lymphocyte count increased: Grade 3000000
Lymphocyte count increased: Grade 4000000
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03: Biochemistry Test Abnormalities

Laboratory parameters included hematological and biochemistry parameters. Biochemistry parameters/abnormalities included alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia and gamma glutamyl transferase Number of participants with biochemistry test abnormalities by grades (NCI CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.

Time frame:
Baseline up to end of treatment (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.03: Biochemistry Test Abnormalities
ParticipantsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Alanine aminotransferase: Grade 1112361
Alanine aminotransferase: Grade 2001130
Alanine aminotransferase: Grade 3010120
Alanine aminotransferase: Grade 4000000
Alkaline phosphatase: Grade 1113690
Alkaline phosphatase: Grade 2000000
Alkaline phosphatase: Grade 3000000
Alkaline phosphatase: Grade 4000000
Aspartate aminotransferase: Grade 1113372
Aspartate aminotransferase: Grade 2000230
Aspartate aminotransferase: Grade 3000010
Aspartate aminotransferase: Grade 4000000
Bilirubin (total): Grade 1000010
Bilirubin (total): Grade 2000000
Bilirubin (total): Grade 3000000
Bilirubin (total): Grade 4000000
Creatinine: Grade 13128162
Creatinine: Grade 2011032
Creatinine: Grade 3000001
Creatinine: Grade 4000000
Hypercalcemia: Grade 1000021
Hypercalcemia: Grade 2000000
Hypercalcemia: Grade 3000000
Hypercalcemia: Grade 4000000
Hyperglycemia: Grade 12134133
Hyperglycemia: Grade 2000451
Hyperglycemia: Grade 3010010
Hyperglycemia: Grade 4000000
Hyperkalemia: Grade 1001150
Hyperkalemia: Grade 2000010
Hyperkalemia: Grade 3000000
Hyperkalemia: Grade 4000000
Hypermagnesemia: Grade 1001131
Hypermagnesemia: Grade 2000000
Hypermagnesemia: Grade 3000000
Hypermagnesemia: Grade 4000000
Hypernatremia: Grade 1000010
Hypernatremia: Grade 2000000
Hypernatremia: Grade 3000000
Hypernatremia: Grade 4000000
Hypoalbuminemia: Grade 1220130
Hypoalbuminemia: Grade 2001364
Hypoalbuminemia: Grade 3000020
Hypoalbuminemia: Grade 4000000
Hypocalcemia: Grade 1001192
Hypocalcemia: Grade 2000021
Hypocalcemia: Grade 3000000
Hypocalcemia: Grade 4000000
Hypoglycemia: Grade 1000040
Hypoglycemia: Grade 2000020
Hypoglycemia: Grade 3000000
Hypoglycemia: Grade 4000000
Hypokalemia: Grade 1000010
Hypokalemia: Grade 2000000
Hypokalemia: Grade 3002000
Hypokalemia: Grade 4000000
Hypomagnesemia: Grade 1002021
Hypomagnesemia: Grade 2000000
Hypomagnesemia: Grade 3000000
Hypomagnesemia: Grade 4000000
Hyponatremia: Grade 1010251
Hyponatremia: Grade 2000000
Hyponatremia: Grade 3000100
Hyponatremia: Grade 4000000
Hypophosphatemia: Grade 1000000
Hypophosphatemia: Grade 2011463
Hypophosphatemia: Grade 3000151
Hypophosphatemia: Grade 4000000
Gamma glutamyl transferase : Grade 1000000
Gamma glutamyl transferase : Grade 2000000
Gamma glutamyl transferase : Grade 3000000
Gamma glutamyl transferase : Grade 4000000
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment Visit
Time frame:
Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 6, 12, 24; and end of treatment (up to a maximum duration of 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment Visit
millimeters of mercury (mmHg)Dose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
SBP: At Baseline115.7 ± 13.66116.2 ± 4.91124.8 ± 9.17113.6 ± 12.16131.4 ± 15.58139.7 ± 14.41
SBP: Change at Cycle 1 Day 12.0 ± 7.2517.3 ± 2.2514.5 ± 14.7615.5 ± 14.92-1.7 ± 19.34—
SBP: Change at Cycle 1 Day 156.8 ± 9.003.5 ± 10.048.7 ± 9.4512.0 ± 18.214.2 ± 17.06-1.9 ± 9.47
SBP: Change at Cycle 2 Day 10.7 ± 8.134.3 ± 3.330.7 ± 9.810.9 ± 7.47-1.8 ± 10.40-11.5 ± 20.04
SBP: Change at Cycle 4 Day 1—3.5-5.8 ± 8.012.3 ± 17.01-0.4 ± 12.75-14.2 ± 7.54
SBP: Change at Cycle 6 Day 1—-15.09.8 ± 19.451.5 ± 15.900.3 ± 18.57-10.4 ± 17.50
SBP: Change at Cycle 12 Day 1—-7.5-7.0-7.3 ± 1.77-5.8 ± 14.54-14.0 ± 2.83
SBP: Change at Cycle 24 Day 1——7.09.0-9.0—
SBP: End of Treatment-7.0 ± 13.44-4.8 ± 10.25-14.0 ± 17.584.9 ± 9.32-0.7 ± 15.17-12.4 ± 22.00
DBP: At Baseline76.8 ± 11.9983.0 ± 4.7783.5 ± 3.0375.8 ± 7.6678.5 ± 10.5976.7 ± 10.37
DBP: Change at Cycle 1 Day 12.1 ± 4.574.2 ± 7.774.8 ± 5.307.0 ± 11.235.3 ± 8.84—
DBP: Change at Cycle 1 Day 150.7 ± 12.34-2.2 ± 1.042.5 ± 11.653.9 ± 8.511.8 ± 10.43-7.5 ± 10.54
DBP: Change at Cycle 2 Day 1-2.8 ± 7.09-2.3 ± 2.570.5 ± 3.12-2.3 ± 5.610.5 ± 8.36-2.4 ± 6.01
DBP: Change at Cycle 4 Day 1—3.0-4.8 ± 2.02-2.6 ± 7.94-1.0 ± 10.24-4.7 ± 4.89
DBP: Change at Cycle 6 Day 1—-17.5-0.5 ± 14.14-6.0 ± 4.92-3.0 ± 13.62-1.4 ± 12.96
DBP: Change at Cycle 12 Day 1—-7.02.5-7.5 ± 7.07-0.3 ± 11.25-5.5 ± 1.41
DBP: Change at Cycle 24 Day 1——-1.07.0-6.5—
DBP: End of Treatment-1.5 ± 4.44-4.5 ± 4.24-6.2 ± 8.13-2.3 ± 9.58-2.8 ± 10.94-4.8 ± 11.17
SecondaryChange From Baseline in Pulse Rate at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment
Time frame:
Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 6, 12, 24; and end of treatment (any time up to a maximum duration of 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Pulse Rate at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment
beats per minute (bpm)Dose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Pulse Rate: At Baseline88.4 ± 21.7681.2 ± 4.2582.6 ± 15.0580.9 ± 7.7073.9 ± 14.7177.4 ± 11.66
Pulse Rate: Change at Cycle 1 Day 1-0.6 ± 9.445.3 ± 9.29-7.8 ± 1.44-0.3 ± 9.15-0.0 ± 12.25—
Pulse Rate: Change at Cycle 1 Day 15-16.0 ± 7.26-12.7 ± 6.33-7.7 ± 26.63-8.1 ± 9.20-3.8 ± 11.55-14.1 ± 11.93
Pulse Rate: Change at Cycle 2 Day 1-10.8 ± 15.25-1.5 ± 6.14-8.2 ± 23.91-0.4 ± 12.09-7.5 ± 11.39-15.3 ± 13.26
Pulse Rate: Change at Cycle 4 Day 1—-4.0-9.7 ± 4.54-3.7 ± 8.45-0.4 ± 16.15-11.1 ± 7.97
Pulse Rate: Change at Cycle 6 Day 1—-7.0-7.5 ± 7.78-8.5 ± 13.31-4.7 ± 18.60-3.1 ± 23.69
Pulse Rate: Change at Cycle 12 Day 1—1.010.0-4.8 ± 6.72-2.8 ± 9.75-2.5 ± 7.78
Pulse Rate: Change at Cycle 24 Day 1——-11.0-20.52.0—
Pulse Rate: Change at End of Treatment-19.3 ± 11.598.0 ± 12.73-2.8 ± 12.89-1.2 ± 11.555.4 ± 20.4217.6 ± 18.80
SecondaryChange From Baseline in Body Weight at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment
Time frame:
Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 4, 6, 12, 24; and end of treatment (any time up to a maximum duration of 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Reported as:
Mean · kilograms
Change From Baseline in Body Weight at Day 1, 15 of Cycle 1, Day 1 of Cycles 2, 4, 6, 12, 24 and End of Treatment
kilogramsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Body Weight: At Baseline74.96 ± 11.33987.43 ± 9.68478.46 ± 13.93882.63 ± 18.34686.54 ± 17.04493.00 ± 17.820
Body Weight: Change at Cycle 1 Day 1-1.03 ± 0.379-1.43 ± 0.751-1.51 ± 1.917-0.98 ± 0.829-0.63 ± 2.227—
Body Weight: Cycle 1 Day 15-1.17 ± 1.747-3.87 ± 2.003-2.40 ± 3.064-1.56 ± 1.565-1.16 ± 2.305-1.72 ± 1.648
Body Weight: Change at Cycle 2 Day 1-2.08 ± 3.123-6.27 ± 2.403-3.92 ± 3.806-2.28 ± 2.689-2.04 ± 3.109-1.21 ± 3.734
Body Weight: Change at Cycle 4 Day 1—-2.60-5.77 ± 5.228-3.36 ± 2.783-4.22 ± 4.118-2.80 ± 3.609
Body Weight: Change at Cycle 6 Day 1—-3.63-14.06-3.82 ± 5.538-4.18 ± 5.232-4.57 ± 6.264
Body Weight: Change at Cycle 12 Day 1—-4.20-11.402.11 ± 2.786-3.53 ± 4.366-6.15 ± 5.162
Body Weight: Change at Cycle 24 Day 1——-16.508.16-2.40—
Body Weight: Change at End of Treatment-2.17 ± 5.327-6.45 ± 6.576-13.60 ± 7.400-2.05 ± 7.134-5.46 ± 5.505-10.68 ± 9.058
SecondaryNumber of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG-PS) to Worst Value

ECOG-PS: used to assess how disease affected the daily living abilities of participant. It ranges on the scale from: 0-5 (0=fully active/able to carry on all pre-disease activities without restriction;1=restricted in physically strenuous activity but ambulatory/able to carry out light/sedentary work;2=ambulatory \[for more than (\>)50%of waking hours\], capable of all self-care but unable to carry out any work activities;3=capable of limited self-care, confined to bed or chair \[for \>50% of waking hours\];4=completely disabled, not capable of any self-care, totally confined to bed or chair;5= dead, higher score=more functional impairment) and changes to worst status scores were presented. Baseline value=value collected prior to first dose of study drug on Cycle 1 Day 1. Worst post-baseline value=worst value between first dose of any study drug and end of treatment (EOT) visit. Shift to low refers to lower than Baseline value; shift to high refers to higher than baseline value for ECOG-PS.

Time frame:
Baseline, End of Treatment (up to Cycle 35 [for Part 1] and up to Cycle 35 [for Part 2], each cycle 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG-PS) to Worst Value
ParticipantsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Baseline 0, EOT 0000031
Baseline 0, EOT 1112180
Baseline 0, EOT 2000200
Baseline 0, EOT 3000100
Baseline 0, EOT 4000000
Baseline 1, EOT 0000000
Baseline 1, EOT 1310672
Baseline 1, EOT 2101022
Baseline 1, EOT 3010010
Baseline 1, EOT 4000000
Baseline 2, EOT 0000000
Baseline 2, EOT 1000000
Baseline 2, EOT 2000001
Baseline 2, EOT 3000000
Baseline 2, EOT 4000000
Baseline 3, EOT 0000000
Baseline 3, EOT 1000000
Baseline 3, EOT 2000000
Baseline 3, EOT 3000000
Baseline 3, EOT 4000000
Baseline 4, EOT 0000000
Baseline 4, EOT 1000000
Baseline 4, EOT 2000000
Baseline 4, EOT 3000000
Baseline 4, EOT 4000000
SecondaryNumber of Participants With Maximum Increase From Baseline in QTc Interval

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Number of participants with maximum increase from baseline of less than (\<) 30 milliseconds (msec), 30 to \<60 msec and greater than or equal to (\>=) 60 msec were reported.

Time frame:
Baseline, End of Treatment (up to Cycle 35 [for Part 1] and up to Cycle 35 [for Part 2], each cycle 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Maximum Increase From Baseline in QTc Interval
ParticipantsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
QTcF (msec): <302128164
QTcF (msec): 30-60220142
QTcF (msec): >=60000100
QTcB (msec): <303118154
QTcB (msec): 30 - 60121152
QTcB (msec): >=60000100
SecondaryMaximum Observed Plasma Concentration (Cmax) of Axitinib and Crizotinib

Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.

Time frame:
Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15
Reported as:
Geometric mean · nanogram per milliliter
Maximum Observed Plasma Concentration (Cmax) of Axitinib and Crizotinib
nanogram per milliliterDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg
Axitinib: Lead-in Day 78.777 ± 3421.33 ± 1231.31 ± 3125.32 ± 10140.21 ± 34
Axitinib: Cycle 1 Day 156.532 ± 5524.28 ± 11530.89 ± 3325.02 ± 7740.91 ± 55
Crizotinib: Cycle 1 Day 15194.8 ± 6230.8 ± 35169.9 ± 298207.0 ± 43235.9 ± 99
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib and Crizotinib

Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.

Time frame:
Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Axitinib and Crizotinib
hoursDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg
Axitinib: Lead-in Day 72.09 (2.03 to 2.15)2.00 (1.03 to 2.00)2.48 (1.95 to 3.00)3.49 (1.00 to 4.00)2.00 (1.00 to 3.98)
Axitinib: Cycle 1 Day 151.50 (1.00 to 2.00)3.00 (3.00 to 6.00)1.50 (1.00 to 2.00)1.50 (1.00 to 2.00)2.00 (1.00 to 3.00)
Crizotinib: Cycle 1 Day 1512.00 (12.00 to 12.00)3.92 (3.07 to 6.00)7.00 (2.00 to 12.00)3.00 (1.00 to 8.00)3.22 (1.00 to 8.08)
SecondaryArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Axitinib and Crizotinib

Area under the plasma concentration versus time-curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours. Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.

Time frame:
Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15
Reported as:
Geometric mean · nanogram*hour per milliliter
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Axitinib and Crizotinib
nanogram*hour per milliliterDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg
Axitinib: Lead-in Day 731.96 ± 61105.9 ± 29131.6 ± 14993.22 ± 135197.8 ± 46
Axitinib: Cycle 1 Day 1534.87 ± 65143.8 ± 107196.8 ± 6127.4 ± 121208.6 ± 35
Crizotinib: Cycle 1 Day 151905 ± 102162 ± 331526 ± 3161985 ± 412144 ± 105
SecondaryApparent Oral Clearance (CL/F) of Axitinib and Crizotinib

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent oral clearance was obtained by dividing study drug dose with AUCtau, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval. Data of this outcome measure was not planned to be analyzed for Cohort 2 in dose expansion part, as pre-specified in protocol.

Time frame:
Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15
Reported as:
Geometric mean · liters per hour
Apparent Oral Clearance (CL/F) of Axitinib and Crizotinib
liters per hourDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg
Axitinib: Lead-in Day 794.06 ± 6128.32 ± 2938.03 ± 14953.70 ± 13425.32 ± 46
Axitinib: Cycle 1 Day 1586.03 ± 6520.86 ± 10725.38 ± 639.28 ± 12123.96 ± 35
Crizotinib: Cycle 1 Day 15105.0 ± 10115.7 ± 33131.2 ± 316126.0 ± 41116.6 ± 105
SecondaryApparent Volume of Distribution (Vz/F) of Axitinib and Crizotinib

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Axitinib: Pre-dose (0 hour [hr]), 1, 2, 3, 4, 6, 8 hrs post-dose at Lead-in Day 7, Cycle 1 Day 15; Crizotinib: pre-dose (0 hr), 1, 2, 3, 4, 6, 8 hrs post-dose at Cycle 1 Day 15

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Objective Response

Percentage of participants with objective response based on assessment of confirmed complete response \[CR\] or confirmed partial response \[PR\] according to Response Evaluation Criteria In Solid Tumors \[RECIST\] version1.1 were reported. Confirmed responses were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

Time frame:
From Baseline until disease progression or death, whichever occurred first (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response
percentage of participantsDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Percentage of Participants With Objective Response0 (0.0 to 60.2)0 (0.0 to 70.8)0 (0.0 to 70.8)0 (0.0 to 33.6)40.0 (19.1 to 63.9)14.3 (0.4 to 57.9)
SecondaryDose Expansion Part: Duration of Response

Duration of response (as per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as the time (in months) from first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) until the first date that recurrent, progressive disease, or death (whichever occurred first). CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. Progression was defined as \>= 20 percent increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.

Time frame:
From first objective response until first recurrent, disease progression, or death, whichever occurred first (up to 35 cycles, each cycle 28 days)
Reported as:
Median · months
Dose Expansion Part: Duration of Response
monthsDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Dose Expansion Part: Duration of Response9.7 (3.6 to 28.6)NA (NA to NA)
SecondaryDose Expansion Part: Progression-Free Survival (PFS)

PFS (as per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) was defined as the time (in months) from start of study treatment to first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date minus date of first dose of study medication plus 1) divided by 30.44. Progression was defined as \>= 20 percent increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions. PFS was not estimated in Dose Expansion Cohort 2 due to small sample size.

Time frame:
From Baseline until disease progression or death, whichever occurred first (up to 35 cycles, each cycle 28 days)
Reported as:
Median · months
Dose Expansion Part: Progression-Free Survival (PFS)
monthsDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Dose Expansion Part: Progression-Free Survival (PFS)5.6 (3.5 to 13.6)NA (NA to NA)
SecondaryDose Expansion Part Cohort 1: Levels of Serum Soluble Protein Biomarkers

Serum soluble protein biomarkers included angiopoietin-2, Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor Receptor 3 (VEGFR 3). Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.

Time frame:
Baseline, Cycle 2 Day 1, end of treatment (up to 35 cycles, each cycle 28 days)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Dose Expansion Part Cohort 1: Levels of Serum Soluble Protein Biomarkers
nanograms per milliliter (ng/mL)Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg
Angiopoietin-2: Baseline4.84 ± 5.282
Angiopoietin-2: Cycle 2 Day 13.81 ± 2.351
Angiopoietin-2: End of Treatment5.44 ± 2.996
HGF: Baseline9.59 ± 4.831
HGF: Cycle 2 Day 115.58 ± 22.897
HGF: End of Treatment11.95 ± 5.237
VEGFR3: Baseline35.368 ± 8.6166
VEGFR3: Cycle 2 Day 126.000 ± 8.3314
VEGFR3: End of Treatment36.444 ± 20.2426
SecondaryDose Expansion Part Cohort 1: Change From Baseline in Serum Concentration of Circulating microRNAs (miRNA) at End of Treatment
Time frame:
Baseline, end of treatment (up to 35 cycles, each cycle 28 days)

No measurements were reported for this outcome.

SecondaryDose Expansion Part Cohort 1: Percentage of c-MET Positive Tumor Cell at Baseline in Relation to Objective Response Rate (ORR)

Percentage of c-MET positive tumor cell for objective response (complete response \[CR\] + partial response \[PR\]) is reported. Objective response was defined as CR and PR. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.

Time frame:
Baseline
Reported as:
Mean · percentage of positive tumor cells
Dose Expansion Part Cohort 1: Percentage of c-MET Positive Tumor Cell at Baseline in Relation to Objective Response Rate (ORR)
percentage of positive tumor cellsDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg
Percent positive cell c-MET Cytoplasmic: CR +PR70.0 ± 25.50
Percent positive cell c-MET Membrane: CR + PR85.0 ± 20.62
SecondaryDose Expansion Part Cohort 1: Level of Plasma Soluble Protein Biomarker (c-MET)

Plasma soluble protein biomarker included c-MET. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.

Time frame:
Baseline; Day 1 and 15 of Cycle 1; Day 1 of Cycles 2, 3, 5; end of treatment (up to 35 cycles, each cycle 28 days)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Dose Expansion Part Cohort 1: Level of Plasma Soluble Protein Biomarker (c-MET)
nanogram per milliliter (ng/mL)Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg
c-MET: Baseline640.0 ± 120.77
c-MET: Cycle 1 Day 1667.4 ± 117.09
c-MET: Cycle 1 Day 15694.8 ± 143.41
c-MET: Cycle 2 Day 1757.1 ± 148.75
c-MET: Cycle 3 Day 1678.2 ± 120.46
c-MET: Cycle 5 Day 1689.8 ± 158.09
c-MET: End of Treatment759.0 ± 183.74
SecondaryDose Expansion Part Cohort 1: Ratio of Serum Soluble Protein Biomarkers Level to Baseline Biomarkers Level by Each Timepoint

Serum soluble protein biomarkers included angiopoietin-2, Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor Receptor 3 (VEGFR3). Ratio=value of serum soluble protein biomarkers at each time point to the value at baseline. Biomarker analysis was not planned to be performed in dose escalation part and Cohort 2 of dose expansion part, as pre-specified in protocol.

Time frame:
Baseline, Cycle 2 Day 1, end of treatment (up to 35 cycles, each cycle 28 days)
Reported as:
Mean · ratio
Dose Expansion Part Cohort 1: Ratio of Serum Soluble Protein Biomarkers Level to Baseline Biomarkers Level by Each Timepoint
ratioDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg
Angiopoietin-2- (Cycle 2 Day 1 ratio Baseline)0.90 ± 0.321
Angiopoietin-2 (End of Treatment ratio Baseline)1.50 ± 1.056
HGF (Cycle 2 Day 1 ratio Baseline)1.62 ± 1.449
HGF (End of Treatment ratio Baseline)1.18 ± 0.278
VEGFR3 (Cycle 2 Day 1 ratio Baseline)0.748 ± 0.1869
VEGFR3 (End of Treatment ratio Baseline)0.969 ± 0.6246

Adverse events

Collected over Baseline up to end of treatment (up to 35 cycles in Part 1 and 35 cycles in Part 2, each cycle 28 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg0/5 (0%)2/5 (40%)5/5 (100%)
Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg0/4 (0%)0/4 (0%)3/4 (75%)
Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg0/10 (0%)5/10 (50%)10/10 (100%)
Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg2/21 (9.5%)8/21 (38.1%)21/21 (100%)
Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg1/7 (14.3%)3/7 (42.9%)7/7 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
NauseaGastrointestinal disorders0/51/30/40/100/210/7
VomitingGastrointestinal disorders0/51/30/40/100/210/7
Disease progressionGeneral disorders0/51/30/40/102/210/7
Deep vein thrombosisVascular disorders0/51/30/40/100/210/7
Acute kidney injuryRenal and urinary disorders0/50/30/41/100/212/7
DiarrhoeaGastrointestinal disorders1/50/30/40/100/211/7
Urinary tract infectionInfections and infestations1/50/30/40/100/210/7
EmbolismVascular disorders0/50/30/42/101/210/7
Non-cardiac chest painGeneral disorders0/50/30/40/100/211/7
SepsisInfections and infestations0/50/30/40/100/211/7
Most frequent other events
Showing 10 of 122
Most frequent other events
EventDose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg
Decreased appetiteMetabolism and nutrition disorders2/53/33/45/107/211/7
NauseaGastrointestinal disorders2/50/32/47/1019/212/7
VomitingGastrointestinal disorders4/51/32/45/1012/211/7
DiarrhoeaGastrointestinal disorders3/50/33/46/1016/214/7
FatigueGeneral disorders1/52/33/47/109/215/7
HypothyroidismEndocrine disorders2/52/32/41/103/210/7
Abdominal painGastrointestinal disorders0/52/30/40/103/211/7
ConstipationGastrointestinal disorders1/52/32/42/103/213/7
ProteinuriaRenal and urinary disorders3/52/30/43/105/210/7
DysphoniaRespiratory, thoracic and mediastinal disorders0/52/31/44/1011/212/7

Baseline characteristics

Safety analysis population included all enrolled participants who received at least 1 dose of axitinib or crizotinib.

Age, Continuous
Age, Continuous(years)Dose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mgTotal
Mean63.2 ± 2.248.7 ± 14.560.3 ± 6.263.9 ± 6.062.4 ± 7.961.9 ± 8.961.7 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mgTotal
Female11356016
Male421515734
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation Part: Crizotinib 200mg+Axitinib 3mgDose Escalation Part: Crizotinib 250mg+Axitinib 3mgDose Escalation Part: Crizotinib 200 mg+Axitinib 5 mgDose Escalation Part: Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mgDose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mgTotal
White5321021546
Black0010012
Asian0000011
Other0010001
08

Study locations

17 sites
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Investigational Drug Services IUHSCC
    Indianapolis, Indiana 46202, United States
  • IU Health University Hospital
    Indianapolis, Indiana 46202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Wayne State University, Dept. of Oncology
    Detroit, Michigan 48201, United States
  • University of Minnesota Health Clinics and Surgery Center
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota Medical Center, Fairview IDS Pharmacy
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota Medical Center, Fairview
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota Physicians Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Cleveland Clinic Taussig Cancer Center Investigational Pharmacy
    Cleveland, Ohio 44106, United States
  • Huntsman Cancer Hospital
    Salt Lake City, Utah 84112, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • John A Moran Eye Center
    Salt Lake City, Utah 84132, United States
  • University Station Ophthalmology Clinic
    Madison, Wisconsin 53705, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • St Bartholomew's Hospital - Barts Health NHS Trust
    London, EC1A 7BE, United Kingdom
  • The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
09

References and documents

Publications

  • Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist. 2019 Sep;24(9):1151-e817. doi: 10.1634/theoncologist.2018-0749. Epub 2019 Jun 6. PubMed 31171735 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Feb 2017, 35 months.

Results were first posted in Jun 2019, 2 years 3 months after primary completion.

Of 41 industry-sponsored phase 1 interventional studies under Carcinoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 68. This study's 35 months is close to that.

Counting every sponsor, half of 70 studies reached it within 46 months; a quarter within 30 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2013
First posted
Dec 3, 2013
StartActual
Feb 26, 2014
Primary completionActual
Feb 22, 2017
CompletionActual
Sep 5, 2019
Results first posted
Jun 21, 2019
Last update
Sep 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01999972
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 3, 2013
Start date
Feb 26, 2014
Primary completion
Feb 22, 2017
Completion
Sep 5, 2019
Results posted
Jun 21, 2019
Last update
Sep 24, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Axitinib · Crizotinib

Start the discussion